Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam
02:27pm, Thursday, 18'th Nov 2021
Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The second Phase 3 study is designed to evaluate the safety and efficac
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
02:15pm, Thursday, 18'th Nov 2021 GlobeNewswire Inc.
Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer’s Disease Second Phase 3 Study is Designed to Evaluate Safety and Efficac
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
01:43pm, Thursday, 18'th Nov 2021 Zacks Investment Research
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
Is An Accelerated Approval Likely For Cassava Sciences?
11:28am, Thursday, 18'th Nov 2021
Cassava Sciences is a company with a promising Alzheimer's Drug candidate. The FDA has a process called accelerated approval that allows for drugs to be approved for use before the finishing of drug t
3 Biotech Stocks That Have More Than Tripled so far This Year
11:04am, Thursday, 18'th Nov 2021 The Motley Fool
But can they keep up the momentum?
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
09:57am, Thursday, 18'th Nov 2021
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
3 Biotech Stocks That Have More Than Tripled so far This Year
06:04am, Thursday, 18'th Nov 2021
But can they keep up the momentum?
See Why Cassava Sciences Shares Are Falling On Wednesday?
07:27pm, Wednesday, 17'th Nov 2021 Benzinga
The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA ) manipulated data key to its case for its experimental Alzheimers drug simufilam. The report comes just two days after Cassava, in an SEC filing, revealed that certain government agencies Full story available on Benzinga.com
Why Cassava Sciences Is Sliding Lower Today
06:14pm, Wednesday, 17'th Nov 2021 The Motley Fool
Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.
See Why Cassava Sciences Shares Are Falling On Wednesday?
02:27pm, Wednesday, 17'th Nov 2021
The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simuf
Why Cassava Sciences Is Sliding Lower Today
01:14pm, Wednesday, 17'th Nov 2021
Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.
Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
12:45pm, Wednesday, 17'th Nov 2021
Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! The post Today's Hot Penny Stocks: What's Moving ZSAN, AVGR
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
12:11pm, Thursday, 11'th Nov 2021
Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, Hi
Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?
10:30am, Thursday, 11'th Nov 2021
Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a w
Cassava Sciences: Cash Is King
10:14pm, Wednesday, 10'th Nov 2021
The company's Q3 earnings "missed" expectations which is laughable. Cassava is increasing spending to get its phase 3 trials off the ground.
